• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Look Into Healthcare Sector Value Stocks

    2/28/22 9:43:29 AM ET
    $DGX
    $IRWD
    $TMBR
    $TVTY
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DGX alert in real time by email

    What is a Value Stock?

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    The following stocks are considered to be notable value stocks in the healthcare sector:

    1. Tivity Health (NASDAQ:TVTY) - P/E: 9.13
    2. Quest Diagnostics (NYSE:DGX) - P/E: 8.5
    3. Xtant Medical Holdings (AMEX:XTNT) - P/E: 3.56
    4. Timber Pharmaceuticals (AMEX:TMBR) - P/E: 2.23
    5. Ironwood Pharmaceuticals (NASDAQ:IRWD) - P/E: 3.44

    Tivity Health saw a decrease in earnings per share from 0.42 in Q3 to $0.3 now. This quarter, Quest Diagnostics experienced a decrease in earnings per share, which was $3.96 in Q3 and is now $3.33. Most recently, the company reported a dividend yield of 1.94%, which has increased by 0.26% from last quarter's yield of 1.68%.

    Xtant Medical Holdings has reported Q3 earnings per share at $-0.02, which has decreased by 100.0% compared to Q2, which was -0.01. Timber Pharmaceuticals has been featured as a value stock. Timber Pharmaceuticals's Q3 EPS sits at $-0.08, which has not changed since last quarter (Q2). Ironwood Pharmaceuticals has reported Q4 earnings per share at $0.27, which has decreased by 18.18% compared to Q3, which was 0.33.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX
    $IRWD
    $TMBR
    $TVTY

    CompanyDatePrice TargetRatingAnalyst
    Quest Diagnostics Incorporated
    $DGX
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    Ironwood Pharmaceuticals Inc.
    $IRWD
    1/5/2026$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Quest Diagnostics Incorporated
    $DGX
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Overweight → Equal Weight
    Wells Fargo
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Buy → Hold
    Jefferies
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Quest Diagnostics Incorporated
    $DGX
    4/2/2025$195.00Buy
    Redburn Atlantic
    Quest Diagnostics Incorporated
    $DGX
    3/4/2025$185.00Buy → Neutral
    Citigroup
    More analyst ratings

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Ironwood Pharma upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Ironwood Pharma from Mkt Perform to Mkt Outperform and set a new price target of $8.00

    1/5/26 8:35:09 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

    New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care and outcomes.

    2/2/26 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/8/24 4:05:19 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/6/24 4:05:12 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brandt Kevin D bought $49,837 worth of shares (41,670 units at $1.20), increasing direct ownership by 5% to 815,860 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    11/17/23 4:42:41 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DGX
    $IRWD
    $TMBR
    $TVTY
    SEC Filings

    View All

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    2/10/26 6:53:25 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Xtant Medical Holdings Inc.

    8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)

    1/16/26 4:15:32 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    1/12/26 4:37:53 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $1,155,048 worth of shares (5,662 units at $204.00), was granted 48 shares and exercised 5,662 shares at a strike of $121.81, increasing direct ownership by 0.31% to 15,381 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    2/12/26 4:33:09 PM ET
    $DGX
    Medical Specialities
    Health Care

    CFO and Assistant Secretary Neils Scott C covered exercise/tax liability with 8,084 shares, decreasing direct ownership by 0.95% to 843,381 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    1/16/26 5:00:16 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Principal Accounting Officer Silver Ronald sold $162,914 worth of shares (35,416 units at $4.60), decreasing direct ownership by 11% to 276,809 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    1/7/26 4:05:09 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

    Fourth quarter revenues of $2.81 billion, up 7.1% from 2024Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024Full year revenues of $11.04 billion, up 11.8% from 2024Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024   Full year cash from operations of $1.89 billionFull year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagno

    2/10/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

    SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share. The increase is effective with the dividend payable on April 20, 2026 to shareholders of record of Quest Diagnostics common stock on April 6, 2026. With the increase, the annual cash dividend will be $3.44 per share. Additionally, the Board of Directors has increased the Company's

    2/10/26 6:33:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Modivcare Announces Changes to Board of Directors

    Financial and Healthcare Executive Erin L. Russell Brings Decades of Experience in Healthcare Capital Markets and Strategy Modivcare Inc. (the "Company" or "Modivcare") (NASDAQ:MODV), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Erin L. Russell has been appointed to its board of directors (the "Board"), effective February 10, 2025. Ms. Russell brings more than 25 years of experience in the healthcare and financial sectors, with a distinguished track record in capital and credit markets. On the Board, Ms. Russell will be a member of the Audit and Nominating and Govern

    2/14/25 6:00:00 AM ET
    $EHTH
    $KAI
    $MODV
    Specialty Insurers
    Finance
    Industrial Machinery/Components
    Industrials

    $DGX
    $IRWD
    $TMBR
    $TVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

    SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/14/24 3:31:33 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

    SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/12/24 3:47:50 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

    SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/4/24 11:46:39 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care